Westchester-based biotechnology leader earns sixth consecutive Top 10
ranking
ARDSLEY, N.Y.--(BUSINESS WIRE)--
Acorda Therapeutics, Inc. (Nasdaq:ACOR) has been named as one of the
best companies to work for in New York, based on an independent survey
by the Best Companies Group (BCG). This is the sixth consecutive year
Acorda was among the top 10 best employers in the state.
Acorda was ranked third within the category of large employers, defined
as employing more than 250 people. The rankings are determined by
feedback from employees about company culture, benefits and overall job
satisfaction.
“This recognition reflects the satisfaction our associates derive from
our commitment to developing therapies that make a difference in the
lives of people with neurological disorders,” said Ron Cohen, M.D.,
Acorda’s President and CEO. “Bringing novel medicines to market is
challenging. Our success is rooted in the values that we share: open
communication, integrity, perseverance and, not least, having fun along
the way!”
“As a native New Yorker, it’s satisfying to me personally that Acorda is
part of the rapidly growing biotechnology hub in the New York
metropolitan area,” Cohen added.
The Best Places to Work survey was conducted by BCG, an independent
company that manages Best Places to Work programs on state, regional and
national levels. The award is a partnership of the New York State
Society for Human Resource Management, the Business Council of New York,
BCG and Journal Multimedia Corporation.
About Acorda Therapeutics
Founded in 1995, Acorda
Therapeutics is a biotechnology company focused on developing
therapies that restore function and improve the lives of people with
neurological disorders.
Acorda has an industry leading pipeline of novel neurological therapies
addressing a range of disorders, including Parkinson’s disease,
epilepsy, post-stroke walking deficits, migraine, and multiple
sclerosis. Acorda markets three FDA-approved therapies, including AMPYRA® (dalfampridine)
Extended Release Tablets, 10 mg.
For more information, please visit the Company’s website at: www.acorda.com.
Forward Looking Statements
This press release includes forward-looking statements. All statements,
other than statements of historical facts, regarding management's
expectations, beliefs, goals, plans or prospects should be considered
forward-looking. These statements are subject to risks and uncertainties
that could cause actual results to differ materially, including: the
ability to complete the Biotie transaction on a timely basis or at all;
the ability to realize the benefits anticipated from the Biotie and
Civitas transactions, among other reasons because acquired development
programs are generally subject to all the risks inherent in the drug
development process and our knowledge of the risks specifically relevant
to acquired programs generally improves over time; the ability to
successfully integrate Biotie’s operations and Civitas’ operations,
respectively, into our operations; we may need to raise additional funds
to finance our expanded operations and may not be able to do so on
acceptable terms; our ability to successfully market and sell Ampyra in
the U.S.; third party payers (including governmental agencies) may not
reimburse for the use of Ampyra or our other products at acceptable
rates or at all and may impose restrictive prior authorization
requirements that limit or block prescriptions; the risk of unfavorable
results from future studies of Ampyra or from our other research and
development programs, including CVT-301, Plumiaz (diazepam) Nasal Spray,
or any other acquired or in-licensed programs; we may not be able to
complete development of, obtain regulatory approval for, or successfully
market CVT-301, Plumiaz, any other products under development, or the
products that we would acquire if we complete the Biotie transaction;
the occurrence of adverse safety events with our products; delays in
obtaining or failure to obtain and maintain regulatory approval of or to
successfully market Fampyra outside of the U.S. and our dependence on
our collaborator Biogen in connection therewith; competition; failure to
protect our intellectual property, to defend against the intellectual
property claims of others or to obtain third party intellectual property
licenses needed for the commercialization of our products; and failure
to comply with regulatory requirements could result in adverse action by
regulatory agencies.
These and other risks are described in greater detail in our filings
with the Securities and Exchange Commission. We may not actually achieve
the goals or plans described in our forward-looking statements, and
investors should not place undue reliance on these statements.
Forward-looking statements made in this release are made only as of the
date hereof, and we disclaim any intent or obligation to update any
forward-looking statements as a result of developments occurring after
the date of this release.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160504005546/en/
Source: Acorda Therapeutics, Inc.